Merck's strong revenue and EPS growth guidance for 2021, coupled with the strategic spin-off of Organon expected to deliver a significant tax-free dividend, indicate positive short-term momentum. Additionally, the confident management tone and continued focus on a robust pipeline support investor optimism.

[1]